New SCAD Clinical Trial Has Received NIH Funding
Researchers are launching an international study to find the best antiplatelet treatment for this rare heart artery condition.
Updated on Oct. 1, 2026 in Heart Disease
Live Poll
Should medical research prioritize funding for conditions that disproportionately affect women?
The National Institutes of Health has awarded a $2 million grant to the Icahn School of Medicine at Mount Sinai to begin the feasibility phase of the SCAD-ALIGN clinical trial. This international study aims to establish clearer treatment protocols for spontaneous coronary artery dissection, a condition that primarily affects women between 42 and 52 years old.
Why it matters
Current clinical guidelines for managing SCAD were borrowed from research on traditional, cholesterol-related heart attacks, which may not be optimal for this specific condition. This trial seeks to provide the first robust evidence-based approach to antiplatelet therapy for patients living with the condition.
The SCAD-ALIGN trial will initiate a feasibility phase for a study involving 3,500 patients across ten countries. Researchers plan to compare the use of aspirin alone against a dual antiplatelet therapy strategy to assess outcomes like cardiovascular death, heart attack, and recurrence.
The players
Icahn School of Medicine at Mount Sinai
A prominent research institution leading global clinical investigations into cardiac care.
National Heart, Lung, and Blood Institute
The federal agency overseeing research into the causes and treatments of heart, lung, and blood diseases.
The details
Spontaneous coronary artery dissection (SCAD) is characterized by a sudden tear within the wall of a heart artery, which can obstruct blood flow. The trial investigates whether a three-month course of dual antiplatelet therapy offers better protection than aspirin alone, followed by a nine-month period of single antiplatelet medication. This comparative data will help determine if current standard-of-care practices—inherited from general cardiology—require adjustment.
Timeline
October 1, 2026: Mount Sinai received the initial $2 million grant.
Health Landscape
The SCAD-ALIGN clinical trial represents a departure from current practices that rely on evidence from studies designed for typical cholesterol-related heart disease. This study aims to ground the management of spontaneous coronary artery dissection in dedicated, population-specific clinical data.
If you or a family member are living with SCAD, this trial indicates that established treatment guidelines may continue to evolve as new evidence emerges. Any questions regarding your current antiplatelet therapy should be discussed directly with your cardiologist.
The takeaway
The medical community is actively working to fill the evidence gap regarding how to best manage spontaneous coronary artery dissection. Patients should keep track of their treatment plan and consult their physician to discuss how emerging research findings might relate to their specific health history.
Further reading
For more on evolving standards of care, visit Heart Disease.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should medical research prioritize funding for conditions that disproportionately affect women?
